Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.31 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL471786 | 0.89 | CYP19A1 (0.36) | CYP19A1 | |
| SCHEMBL7116412 | 0.72 | CYP19A1 (0.35) | CYP19A1 | |
| SCHEMBL218876 | 0.71 | CYP19A1 (0.36) | CYP19A1AKR1C3AKR1C1 | |
| SCHEMBL5057907 | 0.71 | CYP19A1 (0.36) | CYP19A1AKR1C3AKR1C1 | |
| SCHEMBL28451456 | 0.71 | CYP19A1 (0.36) | CYP19A1AKR1C3AKR1C1 | |
| SCHEMBL2000716 | 0.70 | CYP19A1 (0.36) | CYP19A1 | |
| SCHEMBL5620922 | 0.70 | CYP19A1 (0.36) | CYP19A1 | |
| SCHEMBL8986151 | 0.70 | CYP19A1 (0.36) | CYP19A1 | |
| SCHEMBL612395 | 0.70 | CYP19A1 (0.36) | CYP19A1 | |
| SCHEMBL18053347 | 0.69 | TSHR (0.40) | AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1467979-B1 | FUSED HETEROCYCLIC COMPOUNDS AND ANALOGS THEREOF MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL MYERS SQUIBB CO (US) | 2008-08-13 | — | — | EP | disclosed |
| US-7342034-B2 | Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-03-11 | — | — | US | disclosed |
| US-7342034-B2 | Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-03-11 | — | — | US | disclosed |
| US-7342034-B2 | Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-03-11 | — | — | US | disclosed |
| US-7291637-B2 | Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-06 | — | — | US | disclosed |
| US-7291637-B2 | Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-06 | — | — | US | disclosed |
| US-7291637-B2 | Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-06 | — | — | US | disclosed |
| US-7087636-B2 | Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-08-08 | — | — | US | disclosed |
| EP-1467979-A4 | FUSED HETEROCYCLIC COMPOUNDS AND ANALOGS THEREOF: MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL MYERS SQUIBB CO (US) | 2006-03-15 | — | — | EP | disclosed |
| US-20060020002-A1 | Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function | SALVATI MARK E | 2006-01-26 | — | — | US | disclosed |
| US-20050187273-A1 | Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function | SALVATI MARK E (US) | 2005-08-25 | — | — | US | disclosed |
| EP-1467979-A2 | FUSED HETEROCYCLIC COMPOUNDS AND ANALOGS THEREOF: MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | Bristol-Myers Squibb Company (US) | 2004-10-20 | — | — | EP | disclosed |
| US-20030181728-A1 | Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-25 | — | — | US | disclosed |
| WO-2003053358-A2 | FUSED HETEROCYCLIC COMPOUNDS AND ANALOGS THEREOF: MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060020002-A1 | Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function | NCOA1, NR5A2, NR5A1 | CYP19A1 36/4885AKR1C3 535/4885AKR1C1 1055/4885 |
| US-20050187273-A1 | Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function | NCOA1, NR5A2, NR5A1 | CYP19A1 36/4885AKR1C3 535/4885AKR1C1 1055/4885 |
| US-20030181728-A1 | Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function | NCOA1, NR5A2, NR5A1 | CYP19A1 36/4885AKR1C3 535/4885AKR1C1 1055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.